25,358
Participants
Start Date
May 12, 2016
Primary Completion Date
November 1, 2017
Study Completion Date
November 1, 2017
Canagliflozin
Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
Empagliflozin
Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
Dapagliflozin
Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
Dipeptidyl Peptidase-4 Inhibitor (DPP-4)
Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Glucagon-Like Peptide-1 Agonist (GLP-1)
Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Thiazolidinedione (TZD)
Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Sulfonylureas
Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Insulin
Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
Health ResearchTx, LLC, Trevose
Janssen Research & Development, LLC
INDUSTRY